FRA:BIO Statistics

Total Valuation

FRA:BIO has a market cap or net worth of EUR 1.44 billion. The enterprise value is 1.99 billion.

Market Cap	1.44B
Enterprise Value	1.99B

Important Dates

The last earnings date was Monday, March 31, 2025.

Earnings Date	Mar 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	+3.99%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	20.35M

Valuation Ratios

The trailing PE ratio is 54.41.

PE Ratio	54.41
Forward PE	n/a
PS Ratio	1.98
PB Ratio	2.71
P/TBV Ratio	2.75
P/FCF Ratio	44.61
P/OCF Ratio	23.59
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.18, with an EV/FCF ratio of 61.76.

EV / Earnings	75.33
EV / Sales	2.74
EV / EBITDA	16.18
EV / EBIT	24.14
EV / FCF	61.76

Financial Position

The company has a current ratio of 5.06, with a Debt / Equity ratio of 1.27.

Current Ratio	5.06
Quick Ratio	2.04
Debt / Equity	1.27
Debt / EBITDA	5.28
Debt / FCF	20.86
Interest Coverage	2.86

Financial Efficiency

Return on equity (ROE) is 5.13% and return on invested capital (ROIC) is 4.54%.

Return on Equity (ROE)	5.13%
Return on Assets (ROA)	3.81%
Return on Invested Capital (ROIC)	4.54%
Return on Capital Employed (ROCE)	6.81%
Revenue Per Employee	291,062
Profits Per Employee	10,581
Employee Count	2,495
Asset Turnover	0.51
Inventory Turnover	1.12

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +1.44% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+1.44%
50-Day Moving Average	41.36
200-Day Moving Average	41.58
Relative Strength Index (RSI)	65.56
Average Volume (20 Days)	350

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:BIO had revenue of EUR 726.20 million and earned 26.40 million in profits. Earnings per share was 0.66.

Revenue	726.20M
Gross Profit	223.80M
Operating Income	86.80M
Pretax Income	46.60M
Net Income	26.40M
EBITDA	120.70M
EBIT	86.80M
Earnings Per Share (EPS)	0.66

Full Income Statement

Balance Sheet

The company has 119.50 million in cash and 671.80 million in debt, giving a net cash position of -552.30 million.

Cash & Cash Equivalents	119.50M
Total Debt	671.80M
Net Cash	-552.30M
Net Cash Per Share	n/a
Equity (Book Value)	530.70M
Book Value Per Share	13.41
Working Capital	649.40M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 60.90 million and capital expenditures -28.70 million, giving a free cash flow of 32.20 million.

Operating Cash Flow	60.90M
Capital Expenditures	-28.70M
Free Cash Flow	32.20M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 30.82%, with operating and profit margins of 11.95% and 3.64%.

Gross Margin	30.82%
Operating Margin	11.95%
Pretax Margin	6.42%
Profit Margin	3.64%
EBITDA Margin	16.62%
EBIT Margin	11.95%
FCF Margin	4.43%

Dividends & Yields

FRA:BIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	6.06%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	1.84%
FCF Yield	2.24%

Stock Splits

The last stock split was on July 15, 2015. It was a forward split with a ratio of 3.

Last Split Date	Jul 15, 2015
Split Type	Forward
Split Ratio	3

Scores

FRA:BIO has an Altman Z-Score of 2.43. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.43
Piotroski F-Score	n/a